New uses for old drugs: neonatal diabetes and sulphonylureas.
The discovery that their neonatal diabetes is caused by gain-of-function mutations in the K(ATP) channel has enabled many patients to switch from insulin to oral sulphonylurea drugs. Here, I review molecular, physiological, and clinical features of this change in therapy.
Ashcroft
Frances M
FM
Henry Wellcome Centre for Gene Function, Department of Physiology, Anatomy and Genetics, University of Oxford, UK. frances.ashcroft@dpag.ox.ac.uk
D000818:Animals; D003920:Diabetes Mellitus / Q000151:congenital* / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D054086:KATP Channels / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D009154:Mutation; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D007328:Insulin; D054086:KATP Channels; D013453:Sulfonylurea Compounds